Phuturdex › Diseases › Sarcoma
Drugs in development · updated 30 October 2026
Sarcoma: drugs in development
As of 30 October 2026 there are 205 active clinical trials (recruiting or ongoing, phases I–III) on 204 drugs for sarcoma. 94 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 94 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DoxorubicinAdriamycin, Doxorubincin | III | 21 | NCT03805022 |
| Ifosfamide | III | 10 | NCT03805022 |
| TrabectedinYondelis®, Trabectedin Accord® | III | 7 | NCT06263231 |
| EribulinEribulin Mesilate injection, Eribulin Mcsilate Injection | III | 5 | NCT06263231 |
| PazopanibVotrient® | III | 5 | NCT06263231 |
| TislelizumabTisleizumab, Tiselizumab | III | 5 | NCT06332274 |
| DacarbazineDTIC, Dtic-Dome® | III | 4 | NCT03016819 |
| CisplatinCis Platinum, Cisplatine | III | 3 | NCT00470223 |
| EtoposideAvopef®, Etopophos Preservative Free® | III | 3 | NCT00470223 |
| Zoledronic AcidZoledronate, Zoledronic acide | III | 2 | NCT00470223 |
| CapmatinibINC280, Tabrecta® | II–III | 1 | NCT06988475 |
| DigoxinLanoxin®, Lanoxicaps® | III | 1 | NCT03016819 |
| ImatinibSTI571, Imkeldi® | III | 1 | NCT02413736 |
| MethotrexateJylamvo®, Reditrex® | III | 1 | NCT00470223 |
| MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride® | III | 1 | NCT03016819 |
Sorted by most advanced phase and number of active trials. Showing 15 of 110 drugs.
All 204 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Osteosarcoma 101 drugs
- Ewing sarcoma 82 drugs
- Rhabdomyosarcoma 68 drugs
- Neuroblastoma 95 drugs
- Liposarcoma 43 drugs
- Melanoma 352 drugs
- Carcinosarcoma 25 drugs
- Endometrial neoplasm 298 drugs
- Synovial sarcoma 33 drugs
- Metastasis 493 drugs
- Kaposi's sarcoma 15 drugs
- Neurofibrosarcoma 24 drugs
Broader categories
- Neoplasm 671 drugs
- Nerve tissue neoplasm 4 drugs
- Glandular and epithelial neoplasm 12 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Female urogenital disease 11 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012509 “Sarcoma”.